Redmile Group, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001425738

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2023 · 68 positions · Total reported value $2.10B · Top-10 concentration 55.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.2% · 4 new · 23 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +21.6% · vs SPY +6.8% · Prev Value $1.51B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2023 13F filing, Redmile Group, LLC disclosed 68 equity positions with a combined reported value of $2.10B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were IMGN ($277.78M), KRYS ($232.39M), FOLD ($206.05M). By sector, the heaviest allocations are Health Care 53.7%, Consumer Discretionary 0.6%.

Versus the prior quarter, Redmile Group, LLC opened 4 new positions, trimmed 23 and fully exited 0, a turnover rate of 69.2% of positions.

The largest new positions opened in Q3 2023 were IMGN ($277.78M), KRYS ($232.39M), FOLD ($206.05M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • IMGN IMMUNOGEN INC · $277.78M
  • KRYS KRYSTAL BIOTECH INC · $232.39M
  • FOLD AMICUS THERAPEUTICS INC · $206.05M
  • AKRO AKERO THERAPEUTICS INC · $89.51M
  • AUGX AUGMEDIX INC · $80.50M
  • REPL REPLIMUNE GROUP INC · $71.24M
  • LIVN LIVANOVA PLC · $58.19M
  • DCPH DECIPHERA PHARMACEUTICALS IN · $56.93M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Redmile Group, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-08-06 Buy Attovia Therapeutics, Inc. 400,000 $17.00 SEC filing
2026-08-06 Buy Attovia Therapeutics, Inc. 200,000 $17.00 SEC filing
2026-08-06 Conversion Attovia Therapeutics, Inc. 782,854 — SEC filing
2026-07-22 Tax payment Atara Biotherapeutics, Inc. 60 — SEC filing
2026-07-22 Opt exercise Atara Biotherapeutics, Inc. 195,211 — SEC filing
2026-04-20 J FATE THERAPEUTICS INC 8,977,624 — SEC filing

All insider transactions →

Fund Profile

Redmile Group, LLC, based in Larkspur, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $1.49B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: LARKSPUR, CA, United States
  • SEC registration: 801-67747 (status: Approved), registered 2007-04-19
  • Regulatory AUM (Form ADV): $4.70B as of 2026-08-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 20 private funds, of which 10 hedge funds
  • Website: redmilegroup.com

Portfolio Structure

  • 39 positions · $1.49B reported value (Q2 2026)
  • Top 10 holdings = 73.5% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 15.9%
  • Average position size: $38.19M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 5 added, 23 reduced
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

Redmile Group Rebalancing Analysis (2026-Q2) 1. Overall Direction & Market View The fund is taking a cautious stance, significantly reducing positions in most top holdings while maintaining a concentrated focus on healthcare/biotech, suggesting potential profit-taking or rebalancing rather than a major sector shift. 2. Key Moves - Major reductions: SRRK (-52.5%), NRIX (-47.3%), ANNX (-18.4%), ABSI (-18.3%), IMNM (-11.6%) - Only addition in top-10: STTK (+24.4%) - 4 new positions added (not specified) - RGNX held steady 3. Portfolio Structure - Active management with frequent position adjustments - Extreme sector concentration (100% healthcare/biotech in top-10) - Moderate risk appetite with focus on small/mid-cap biotech companies - Recent reductions indicate some risk mitigation 4. Per-Holding Business Identification - SRRK: Scholar Rock - Biotechnology developing muscle-targeted therapies - KRYS: Krystal Biotech - Gene therapy for rare diseases - STOK: Stoke Therapeutics - Neurological disorder treatments - IMNM: Immunome - Antibody discovery and development - NRIX: Nurix Therapeutics - Targeted protein degradation therapies - ABSI: AbSci - Synthetic biology for antibody production - ANNX: Annexon - Neurodegenerative and ophthalmic disease treatments - RGNX: Regenxbio - Gene therapy using NAV technology platform - STTK: Shattuck Labs - Novel immunology therapies - NGNE: Neurogene - Gene therapy for neurological disorders 5. Style Summary The Redmile Group is actively trimming biotech positions while selectively increasing exposure to Shattuck Labs, maintaining a concentrated healthcare focus with cautious risk management.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 53.7%
Materials 0.0%
Other 45.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 17.50M $277.78M 13.22%
13.22%
New
2 2.00M $232.39M 11.06%
11.06%
New
3 16.94M $206.05M 9.80%
9.80%
New
4 1.77M $89.51M 4.26%
4.26%
New
5 15.63M $80.50M 3.83%
3.83%
New
6 4.16M $71.24M 3.39%
3.39%
New
7 1.10M $58.19M 2.77%
2.77%
New
8 4.48M $56.93M 2.71%
2.71%
New
9 2.68M $46.44M 2.21%
2.21%
New
10 1.64M $45.02M 2.14%
2.14%
New
11 2.57M $42.37M 2.02%
2.02%
New
12 1.10M $42.33M 2.01%
2.01%
New
13 1.86M $41.24M 1.96%
1.96%
New
14 774.20K $40.88M 1.95%
1.95%
New
15 873.97K $39.79M 1.89%
1.89%
New
16 155.08K $37.51M 1.78%
1.78%
New
17 85.38K $37.18M 1.77%
1.77%
New
18 5.66M $35.89M 1.71%
1.71%
New
19 1.47M $35.35M 1.68%
1.68%
New
20 4.73M $33.61M 1.60%
1.60%
New
21 929.90K $32.30M 1.54%
1.54%
New
22 59.85K $29.12M 1.39%
1.39%
New
23 2.40M $29.05M 1.38%
1.38%
New
24 13.12M $27.82M 1.32%
1.32%
New
25 1.77M $27.00M 1.28%
1.28%
New
26 1.87M $25.97M 1.24%
1.24%
New
27 94.74K $25.89M 1.23%
1.23%
New
28 2.97M $24.81M 1.18%
1.18%
New
29 244.39K $22.80M 1.08%
1.08%
New
30 2.85M $22.39M 1.06%
1.06%
New
31 1.28M $20.29M 0.96%
0.96%
New
32 2.05M $20.02M 0.95%
0.95%
New
33 3.87M $15.26M 0.73%
0.73%
New
34 8.51M $14.64M 0.70%
0.70%
New
35 419.57K $14.33M 0.68%
0.68%
New
36 518.92K $13.50M 0.64%
0.64%
New
37 66.38K $13.01M 0.62%
0.62%
New
38 14.18M $12.72M 0.60%
0.60%
New
39 465.28K $12.67M 0.60%
0.60%
New
40 1.32M $12.63M 0.60%
0.60%
New
41 761.96K $11.76M 0.56%
0.56%
New
42 809.78K $10.74M 0.51%
0.51%
New
43 8.03M $10.60M 0.50%
0.50%
New
44 4.14M $9.39M 0.45%
0.45%
New
45 6.28M $9.30M 0.44%
0.44%
New
46 5.77M $9.11M 0.43%
0.43%
New
47 5.62M $8.54M 0.41%
0.41%
New
48 3.50M $8.27M 0.39%
0.39%
New
49 19.81M $7.92M 0.38%
0.38%
New
50 427.49K $7.10M 0.34%
0.34%
New

FAQ

What did Redmile Group, LLC buy in 2023-Q3?

In its 2023-Q3 13F filing, Redmile Group, LLC reported 68 equity positions worth $2.10B in aggregate; its largest disclosed positions were IMGN ($277.78M), KRYS ($232.39M), FOLD ($206.05M).

How large is Redmile Group, LLC's portfolio?

Redmile Group, LLC reported $2.10B of long equity holdings across 68 positions as of 2023-Q3. Top-10 holdings account for 55.4% of reported value.

What is Redmile Group, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/redmile/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →